Antibiotic-Resistant Bloodstream Infections Rise 17% in England: Over 400 Cases Weekly, UKHSA Warns

Antibiotic-resistant bloodstream infections in England rose by nearly 17% between 2019 and 2025, according to new surveillance data published by the UK Health Security Agency (UKHSA), translating to more than 400 resistant episodes every single week.

  • The Core Issue: Bacteria have increasingly evolved to withstand common medical treatments, resulting in over 21,000 resistant bloodstream infection episodes across England in 2025.
  • The Slower Growth: While absolute numbers continue to climb, the year-over-year rate of increase slowed to 3.2% between 2024 and 2025, compared to 9.3% in the prior year.
  • The Actionable Rule: Health officials emphasize that cutting antibiotic use alone is insufficient; patients must take antibiotics only when told to do so by a healthcare professional, avoid sharing medications, and stay current on routine vaccinations.

Bloodstream Infection Episodes Increased While Growth Rates Decelerated

Data from the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) release on November 12, 2026, showed that bloodstream infection episodes involving bacteria resistant to at least one specified antibiotic climbed from 18,086 in 2019 up to 21,129 by 2025.

Despite the long-term increase, recent figures show a deceleration in growth. Cases rose by 3.2% between 2024 and 2025, moving from 20,468 to 21,129. This represents a slower pace than the 9.3% jump recorded between 2023 and 2024. Overall antibiotic consumption across the NHS also decreased by 10.7% between 2019 and 2025, falling from 17.8 to 15.9 defined daily doses per 1,000 inhabitants per day.

Escherichia Coli and Klebsiella Pneumoniae Show Varying Resistance Patterns

Escherichia coli continued to represent the greatest burden, contributing roughly 70% of resistant infections. Klebsiella pneumoniae saw its share increase from 11.1% in 2019 to 13.4% in 2025.

Resistance patterns varied significantly among these pathogens. Resistance to piperacillin-tazobactam in K. pneumoniae reached 22.8% in 2025, nearly double the 11.9% observed in E. coli. Meanwhile, co-amoxiclav resistance remained elevated in E. coli isolates, affecting 43.1% of cases.

Antibiotic-Resistant Bloodstream Infections Rise 17% in England: Over 400 Cases Weekly, UKHSA Warns
Photo: Surrey Live
Pathogen Primary Resistant Share (2025) Notable Antibiotic Resistance Metric
Escherichia coli ~70% of resistant episodes 43.1% co-amoxiclav resistance
Klebsiella pneumoniae 13.4% of resistant episodes 22.8% piperacillin-tazobactam resistance

Health Inequalities and Demographic Disparities

The burden of antimicrobial resistance is distributed unevenly across England’s population. Adults aged over 45 accounted for 89.3% of resistant infection cases in 2025, while almost half of cases (49.7%) were detected in people aged over 74.

Socioeconomic deprivation was another significant factor. Ethnic inequalities were also pronounced, with resistance identified in 42.4% of episodes among Asian or Asian British patients and 32.8% among Black, African, Caribbean, or Black British patients, compared with 20.7% in White patients.

Regional variations were also reported. NHS North West London Integrated Care Board recorded the highest rate of resistant infections at 63.3 per 100,000 population, whereas NHS Leicester, Leicestershire and Rutland ICB reported the lowest at 27.4 per 100,000.

Antibiotic-Resistant Bloodstream Infections Rise 17% in England: Over 400 Cases Weekly, UKHSA Warns
Photo: The Pharmacist

Public Health Warnings and the Path Forward

Health authorities cautioned that reducing antibiotic consumption alone will not halt the spread of resistant organisms. Officials pointed out that specified drug-resistant infections remain 25.7% above the baseline set during the 2019–2020 financial year.

“Every week hundreds of people face a new reality of what it means to get an antibiotic-resistant infection, which can increase the risk of serious illness, and even death.”

said Dr Shona Arora, interim chief medical advisor at UKHSA.

Arora added that patients must take active preventive measures alongside clinical stewardship. Because surveillance is also tracking emerging fungal threats such as Candidozyma auris, these outcomes cast doubt on whether the UK National Action Plan for antimicrobial resistance 2024 to 2029 will achieve its goals of preventing increases in specified drug-resistant infections and lessening the impact of severe bacterial diseases.

Follow Clinician-Prescribed Regimens and Avoid Self-Medicating with Antibiotics

Patients diagnosed with bacterial infections must strictly adhere to clinician-prescribed treatment regimens. Individuals should never self-medicate with leftover antibiotics, share prescriptions with family members, or save antimicrobial drugs for future illnesses.

References

  • UK Health Security Agency. ESPAUR report 2025 to 2026: Chapter 2. Antimicrobial resistance (AMR). Published 12th November 2026.
  • UK Health Security Agency. Over 400 antibiotic-resistant infections each week in 2025. Published November 2026.
  • UK Government. UK 5-year action plan for antimicrobial resistance 2024 to 2029. Updated 2024.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Foo Fighters Announce Croke Park Concert for September 2027 with Garbage and Florence Road

Germany, Austria, Greece, Denmark and Netherlands to Unveil Rwanda Deportation Hub